The value of monitoring minimal residual disease in the patients with donor lymphocyte infusion as intervention of relapsed/ refractory acute lymphoblastic leukemia after allogeneic hematopoietic stem cell transplantation

American Journal of Hematology

Volumn 85, Issue 2, 2010, Pages 141-142

  Ma, Xiao ^a   Wu, Depei ^a   Sun, Aining ^a   Qiu, Huiying ^a   Fu, Zhenzhen ^a   Wu, Xiaojin ^a   Chen, Suning ^a   Mohty, Mohamad ^b  

^a SOOCHOW UNIVERSITY   (China)

^b NANTES UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CYTARABINE; METHOTREXATE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CANCER GROWTH; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DONOR LYMPHOCYTE INFUSION; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; MALE; MINIMAL RESIDUAL DISEASE; MONITORING; PRIORITY JOURNAL; RECURRENT DISEASE; REFRACTORY PERIOD; REMISSION; RETROSPECTIVE STUDY; SCHOOL CHILD; TUMOR CELL;

ADOLESCENT; ADULT; CHILD; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOCYTE TRANSFUSION; MALE; MIDDLE AGED; MONITORING, PHYSIOLOGIC; NEOPLASM, RESIDUAL; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; RECURRENCE; TRANSPLANTATION, HOMOLOGOUS;

EID: 75449107730     PISSN: 03618609     EISSN: 10968652     Source Type: Journal    
DOI: 10.1002/ajh.21573     Document Type: Article

References (9)

1. Horowitz MM, Messerer D, Hoelzer D, et al. Chemotherapy compared with bone marrow transplantation for adults with acute lymphoblastic leukemia in first remission. Ann Intern Med 1991;115:13-18.
2. Thiebaut A, Vernant JP, Degos L, et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87 (Review). Hematol Oncol Clin N Amer 2000;14:1353-1366.
3. Dekker AW, Van't Veer MB, Van Der Holt B, et al. Postremission treatment with autologous stem cell transplantation (Auto-SCT) or allogeneic stem cell transplantation (Allo-SCT) in adults with acute lymphoblastic leukemia (ALL). A phase II clinical trial (HOVON 18 ALL). Blood 2001;98:3567a.
4. Schimtz M, Eapen N, Horowitz MM, et al. Long-term outcome of patients given transplants of mobilized blood or bone marrow: A report from the International Bone Marrow Transplant Registry and the European Group for Blood and Marrow Transplantation. Blood 2006;108:4288-4290.
5. Sanchez J, Serrano J, Gomez P, et al. Clinical value of immunological monitoring of minimal residual disease in acute lymphoblastic leukaemia after allogeneic transplantation. Br J Haematol 2002;116:686-694.
6. Szczepanski T, Orfao A, Van Der Velden VHJ, et al. Minimal residual disease in leuemia patients. Lancet Oncol 2001;ii:409-417.
7. Luznik L, Fuchs EJ. Donor lymphocyte infusions to treat hematologic malignancies in relapse after allogeneic blood or marrow transplantation. Cancer Control 2002;9:123-137.
8. Alyea EP, Soiffer RJ, Canning C, et al. Toxicity and efficacy of defined doses of donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. Blood 1998;91:3671-3680.
9. Wetzler M, Dodge RK, Mrozek K, et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. Blood 1999;93:3983-3993.